Vanguard Group Inc. Trims Stock Position in Embecta Corp. $EMBC

Vanguard Group Inc. lowered its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 15.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,617,610 shares of the company’s stock after selling 846,891 shares during the quarter. Vanguard Group Inc. owned approximately 7.80% of Embecta worth $54,857,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EMBC. Ameriprise Financial Inc. increased its position in shares of Embecta by 439.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock valued at $6,878,000 after purchasing an additional 578,174 shares during the last quarter. Jefferies Financial Group Inc. increased its position in shares of Embecta by 40.4% during the 3rd quarter. Jefferies Financial Group Inc. now owns 1,884,875 shares of the company’s stock valued at $26,596,000 after purchasing an additional 542,162 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Embecta during the 4th quarter valued at approximately $5,178,000. Teacher Retirement System of Texas grew its stake in shares of Embecta by 365.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock valued at $5,255,000 after acquiring an additional 292,477 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Embecta during the 3rd quarter valued at approximately $3,547,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $3.14 on Friday. The stock has a 50 day moving average of $8.04 and a 200 day moving average of $10.63. The company has a market cap of $186.29 million, a PE ratio of 1.65 and a beta of 1.09. Embecta Corp. has a 12-month low of $3.08 and a 12-month high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The business had revenue of $221.80 million during the quarter, compared to the consensus estimate of $235.67 million. During the same quarter in the previous year, the company earned $0.70 earnings per share. The company’s revenue for the quarter was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Equities research analysts predict that Embecta Corp. will post 1.58 earnings per share for the current fiscal year.

Embecta Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Thursday, May 28th will be paid a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 1.3%. The ex-dividend date is Thursday, May 28th. Embecta’s dividend payout ratio is presently 2.11%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EMBC. Weiss Ratings downgraded Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, May 6th. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Zacks Research downgraded Embecta from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Mizuho cut their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $15.00.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.